The soluble guanylyl cyclase stimulator riociguat reduces liver fibrosis and portal pressure in cirrhotic rats
P Schwabl, K Brusilovskaya, F Riedl, D Bauer, B Strobel, S Fida, P Supper, H Hayden, M Trauner, M Peck-Radosavljevic, T Reiberger · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: In liver cirrhosis nitric oxide (NO) signaling, including function of its receptor soluble guanylyl cyclase (sGC), is distorted. The sGC stimulator riociguat (RIO) is used as treatment for pulmonary hypertension and it has been shown that RIO acts antifibrotic. We thus aimed to investigate effects of RIO on experimental liver cirrhosis and portal hypertension. Methods: Cirrhosis was induced by carbontetrachloride injections (CCl4, 8 weeks) or by bile duct ligation (BDL, 3 weeks) in Sprague Dawley rats. Controls received olive-oil (OO) or underwent sham operation (SO). RIO (1 mg/kg) or placebo were ga…
